N-Acetyl Cysteine (NAC) has been studied extensively for its potential benefits as a mucolytic agent in various respiratory conditions.
Research has confirmed the ability of NAC to break down disulfide bonds in mucus, thereby reducing its viscosity and making it easier to clear from the respiratory tract.
Studies have consistently shown that NAC can reduce sputum viscosity and improve lung function in patients with chronic bronchitis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).
A study published in the Journal of Thoracic Disease investigated the effects of NAC on sputum properties in patients with stable COPD. The study found that NAC was able to significantly reduce sputum viscosity and elasticity, which improved the ability of patients to clear their airways.
Another study published in the American Journal of Respiratory and Critical Care Medicine investigated the use of NAC in patients with cystic fibrosis. The study found that NAC improved sputum clearance and lung function in the patients.
In addition to its mucolytic properties, NAC has been shown to have anti-inflammatory effects in the respiratory tract. A study published in the European Respiratory Journal investigated the effects of NAC on airway inflammation in patients with COPD. The study found that NAC reduced markers of airway inflammation and improved lung function in the patients.
Overall, research supports the potential of NAC as a mucolytic agent in various respiratory conditions. It can reduce sputum viscosity, improve lung function, and reduce airway inflammation.
Why RN Labs NAC Powder?
Unlike most NAC products, RN Labs NAC is of non-animal origin and suitable for vegans.
This 100% pure NAC has no additives, flavours or other excipients, and has only a mild sulphur taste. NAC has demonstrated antioxidant, anti-inflammatory and mucolytic activity, as well as being an effective enhancer of T-cell function.
DOSE (For Clinical Immune Applications)
500 – 2,000mg/d for focused clinical support and prevention.
Doses as high as 3,000 – 6,000 mg/d have been used during the acute period of an infection.
